Douard Marie Cécile, di Palma Mario, d'Agostino Patricia, Chevret Sylvie, Kriegel Irène, Falissard Bruno, Thierry Patrick, George Brigitte, Bussières Laurence, Misset Jean-Louis
Department of Anesthesiology, Hopital Saint Louis, AP-HP, Université Paris VII, 1, avenue Claude Vellefaux, 75010, Paris, France.
Support Care Cancer. 2006 Feb;14(2):161-6. doi: 10.1007/s00520-005-0852-1. Epub 2005 Aug 11.
To assess the efficacy of equimolar mixture of nitrous oxide/oxygen (EMNO) to prevent pain induced by venous access ports (VAPs) implantation in cancer patients.
In a randomized, double-blind study on an adult population not knowing the effects of EMNO, cancer patients were randomly assigned to breath via a facial mask, EMNO or a placebo mixture comprising 50% oxygen and 50% nitrogen. The primary end-point was the patients' assessment of the severity of pain evaluated using a visual analog scale (VAS, 0 to 100) and the proportion of patients suffering pain in each group. The secondary criteria were side effects, tolerability of EMNO, and the level of satisfaction of both the patients and the medical team.
Eighty-three adults (42 in the EMNO group and 41 in the placebo group) were included. VAPs were implanted in the jugular vein in 95% of patients. In the placebo group, 78% of the patients declared that they found VAP implantation painful vs. 34% in the EMNO group (p=0.001). The severity of the pain was reduced by 50% in the EMNO group in comparison with placebo (p=0.0125). Although the median time to perform implantation was strictly identical in both groups (20 min), the estimated duration of surgery seemed longer to patients in the control group. Patient and investigator satisfaction indexes were >90% in both groups.
EMNO provides an effective solution for the prevention of pain during placement of VAPs.
评估等摩尔一氧化二氮/氧气混合气体(EMNO)预防癌症患者静脉输液港(VAP)植入所致疼痛的疗效。
在一项针对不了解EMNO作用的成年人群的随机双盲研究中,癌症患者被随机分配通过面罩呼吸EMNO或含50%氧气和50%氮气的安慰剂混合气体。主要终点是患者使用视觉模拟量表(VAS,0至100)对疼痛严重程度的评估以及每组中疼痛患者的比例。次要标准为副作用、EMNO的耐受性以及患者和医疗团队的满意度。
纳入83名成年人(EMNO组42名,安慰剂组41名)。95%的患者在颈静脉植入VAP。安慰剂组中,78%的患者称VAP植入有疼痛感,而EMNO组为34%(p = 0.001)。与安慰剂组相比,EMNO组疼痛严重程度降低了50%(p = 0.0125)。尽管两组植入操作的中位时间严格相同(20分钟),但对照组患者感觉手术估计持续时间更长。两组患者和研究者的满意度指数均>90%。
EMNO为预防VAP植入过程中的疼痛提供了一种有效解决方案。